Vip Viprakasit

List of Publications by Year
in descending order

128 papers	2,239 citations	257450 24 h-index	265206 42 g-index
129 all docs	129 docs citations	129 times ranked	1910 citing authors

#	Article	IF	Citations
1	Global Globin Network Consensus Paper: Classification and Stratified Roadmaps for Improved Thalassaemia Care and Prevention in 32 Countries. Journal of Personalized Medicine, 2022, 12, 552.	2.5	6
2	An openâ€label, multicenter, efficacy, and safety study of deferasirox in ironâ€overloaded patients with nonâ€transfusionâ€dependent thalassemia (<scp>THETIS</scp>): 5â€year results. American Journal of Hematology, 2022, 97, .	4.1	2
3	Crushed deferasirox <scp>filmâ€coated</scp> tablets in pediatric patients with transfusional hemosiderosis: Results from a <scp>singleâ€arm</scp>, interventional phase 4 study (<scp>MIMAS</scp>). American Journal of Hematology, 2022, 97, .	4.1	1
4	Clinical outcomes and prognosis of Thai retinoblastoma patients. Pediatrics International, 2021, 63, 671-677.	0.5	2
5	Revisiting the nonâ€transfusionâ€dependent (NTDT) vs. transfusionâ€dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	4.1	28
6	Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatrics International, 2021, 63, 404-409.	0.5	7
7	Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with nonâ€transfusionâ€dependent Î²â€thalassaemia. British Journal of Haematology, 2021, 194, 474-477.	2.5	10
8	Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand. BMC Public Health, 2021, 21, 1177.	2.9	2
9	INVASIVE FUNGAL INFECTION IN CHILDREN WITH ACUTE LEUKEMIA AND SEVERE APLASTIC ANEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021039.	1.3	7
10	An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines. Scientific Reports, 2021, 11, 13283.	3.3	2
11	Severe neonatal haemolytic anaemia caused by compound heterozygous KLF1 mutations: report of four families and literature review. British Journal of Haematology, 2021, 194, 626-634.	2.5	9
12	Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Journal of Blood Medicine, 2021, Volume 12, 679-689.	1.7	1
13	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in Î²-thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644.	2.2	13
14	Improving outcomes and quality of life for patients with transfusion-dependent Î²-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology, 2021, 14, 897-909.	2.2	13
15	An automated liver segmentation in liver iron concentration map using fuzzy c-means clustering combined with anatomical landmark data. BMC Medical Imaging, 2021, 21, 138.	2.7	1
16	Limited Sensitivity of a Rapid SARS-CoV-2 Antigen Detection Assay for Surveillance of Asymptomatic Individuals in Thailand. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1505-1509.	1.4	6
17	Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach. BMC Public Health, 2021, 21, 1796.	2.9	3
18	LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021065.	1.3	2

#	Article	IF	Citations
19	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. Blood, 2021, 138, 3074-3074.	1.4	0
20	A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent Î²-Thalassemia (TDT). Blood, 2021, 138, 4161-4161.	1.4	1
21	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	1.4	1
22	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent Î²-Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	1.4	4
23	Early development of decreased Î²â€cell insulin secretion in children and adolescents with hemoglobin H disease and its relationship with levels of anemia. Pediatric Blood and Cancer, 2020, 67, e28109.	1.5	3
24	Changing patterns in the epidemiology of Î²â€thalassemia. European Journal of Haematology, 2020, 105, 692-703.	2.2	122
25	Paper-based microchip electrophoresis for point-of-care hemoglobin testing. Analyst, The, 2020, 145, 2525-2542.	3.5	39
26	Impact of splenectomy on outcomes of hematopoietic stem cell transplantation in pediatric patients with transfusionâ€dependent thalassemia. Pediatric Blood and Cancer, 2020, 67, e28483.	1.5	2
27	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	1.4	7
28	Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with Î²-Thalassemia in the Believe Trial. Blood, 2020, 136, 47-48.	1.4	8
29	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	1.4	8
30	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. Blood, 2020, 136, 30-32.	1.4	3
31	Co-inheritance of Southeast Asian Ovalocytosis (SAO) and G6PD deficiency associated with acute hemolysis in a Thai patient. Blood Cells, Molecules, and Diseases, 2019, 79, 102347.	1.4	1
32	Quality of life in patients with Î²â€thalassemia: A prospective study of transfusionâ€dependent and nonâ€transfusionâ€dependent patients in Greece, Italy, Lebanon, and Thailand. American Journal of Hematology, 2019, 94, E261-E264.	4.1	21
33	Prevalence of left ventricular diastolic dysfunction by cardiac magnetic resonance imaging in thalassemia major patients with normal left ventricular systolic function. BMC Cardiovascular Disorders, 2019, 19, 245.	1.7	7
34	Effect ofNUDT15on incidence of neutropenia in children with acute lymphoblastic leukemia. Pediatrics International, 2019, 61, 754-758.	0.5	21
35	Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study. Pediatric Hematology and Oncology, 2019, 36, 73-81.	0.8	5
36	Genetic Modifiers in Î²-Thalassemia. Hemoglobin, 2019, 43, 304-304.	0.8	0

#	Article	IF	Citations
37	An integration-free iPSC line (MUSIi008-A) derived from a patient with severe hemolytic anemia carrying compound heterozygote mutations in KLF1 gene for disease modeling. Stem Cell Research, 2019, 34, 101344.	0.7	1
38	Development of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 171-176.	4.1	7
39	Validation of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 177-183.	4.1	7
40	The origin of sickle cell disease in Thailand. International Journal of Laboratory Hematology, 2019, 41, e13-e16.	1.3	2
41	Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood, 2019, 134, 2245-2245.	1.4	7
42	Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 3545-3545.	1.4	3
43	International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification. Blood, 2019, 134, 3373-3373.	1.4	5
44	Estimating the burden of Î±-thalassaemia in Thailand using a comprehensive prevalence database for Southeast Asia. ELife, 2019, 8, .	6.0	15
45	A Longitudinal Study in Elderly Patients with Non-Transfusion Dependent Thalassemia (NTDT) Emphasizes the Size of Splenomegaly Predicts Transfusion Requirement Later in Life. Blood, 2019, 134, 2250-2250.	1.4	0
46	<scp>MRI</scp> for the diagnosis of cardiac and liver iron overload in patients with transfusionâ€dependent thalassemia: An algorithm to guide clinical use when availability is limited. American Journal of Hematology, 2018, 93, E135-E137.	4.1	14
47	Clinical Classification, Screening and Diagnosis for Thalassemia. Hematology/Oncology Clinics of North America, 2018, 32, 193-211.	2.2	123
48	A prospective analysis for prevalence of complications in Thai nontransfusionâ€dependent Hb E/Î²â€thalassemia and Î±â€thalassemia (Hb H disease). American Journal of Hematology, 2018, 93, 623-629.	4.1	18
49	A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Reviews, 2018, 32, 300-311.	5.7	95
50	Serum ferritin in the diagnosis of cardiac and liver iron overload in thalassaemia patients realâ€world practice: a multicentre study. British Journal of Haematology, 2018, 182, 301-305.	2.5	19
51	Interaction between Hb E and Hb Yala (HBB:c.129delT); a novel frameshift beta globin gene mutation, resulting in Hemoglobin E/Î²0 thalassemia. Hematology, 2018, 23, 117-121.	1.5	3
52	Prevalence of low bone mass among adolescents with nontransfusionâ€dependent hemoglobin E/Î²â€thalassemia and its relationship with anemia severity. Pediatric Blood and Cancer, 2018, 65, e26744.	1.5	13
53	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	1.4	11
54	Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand. Blood, 2018, 132, 2228-2228.	1.4	2

#	Article	IF	Citations
55	An Unexpectedly High Frequency of Sptb Gene Mutation (SPTB exon 29: c.6055T>C (p.Ser2019Pro;) Tj ETQq1 1 0.784314 rgBT /Ov Against Malarial Pressure. Blood, 2018, 132, 2322-2322.	1.4	2
56	Iron overload across the spectrum of nonâ€transfusionâ€dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299.	2.5	43
57	Serum ferritin values between 300 and 800 ng/mL in nontransfusionâ€dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. American Journal of Hematology, 2017, 92, E35-E37.	4.1	13
58	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	4.1	10
59	Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world data. Blood Cells, Molecules, and Diseases, 2017, 66, 24-30.	1.4	16
60	Detection of cardiac iron overload with native magnetic resonance T1 and T2 mapping in patients with thalassemia. International Journal of Cardiology, 2017, 248, 421-426.	1.7	31
61	Quality of Life in Patients with Î²-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent. Blood, 2017, 130, 751-751.	1.4	1
62	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078.	4.3	15
63	The genetic basis of asymptomatic codon 8 frameâ€shift (<scp>HBB</scp>:c25_26del<scp>AA</scp>) Î²⁰â€thalassaemia homozygotes. British Journal of Haematology, 2016, 172, 958-965.	2.5	4
64	Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. European Journal of Haematology, 2016, 96, 19-26.	2.2	27
65	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases, 2016, 57, 23-29.	1.4	24
66	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine, 2016, 28, 91-96.	2.2	14
67	Longitudinal Serum Ferritin Cut-Off Level for Cardiac Iron Overload Prediction in Transfusion-Dependent Thalassemia in a Resource Limited Country. Blood, 2016, 128, 1282-1282.	1.4	4
68	Improved R2* liver iron concentration assessment using a novel fuzzy c-mean clustering scheme. BMC Medical Imaging, 2015, 15, 52.	2.7	6
69	Prevalence and distribution of iron overload in patients with transfusionâ€dependent anemias differs across geographic regions: results from the <scp>CORDELIA</scp> study. European Journal of Haematology, 2015, 95, 244-253.	2.2	61
70	Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, 125, 3868-3877.	1.4	67
71	Human primary erythroid cells as a more sensitive alternative in vitro hematological model for nanotoxicity studies: Toxicological effects of silver nanoparticles. Toxicology in Vitro, 2015, 29, 1982-1992.	2.4	10
72	Hemophagocytic lymphohistiocytosis following dengue hemorrhagic fever in Hb H/Hb Constant Spring patient. Pediatrics International, 2015, 57, 763-765.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Long Term Efficacy, Safety and Tolerability (>24 Months) of Twice Daily Dosing of Deferasirox in Transfusion Dependent Thalassemias Who Were Unresponsive to Standard Once Daily Dose. Blood, 2015, 126, 958-958.	1.4	0
74	A Normal Reference of Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry in Healthy Thai Children and Adolescents Aged 5â€“18 Years: A New Reference for Southeast Asian Populations. PLoS ONE, 2014, 9, e97218.	2.5	38
75	Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet Journal of Rare Diseases, 2014, 9, 131.	2.7	30
76	Mutations in KrÃ¼ppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood, 2014, 123, 1586-1595.	1.4	76
77	Clinical Presentation and Molecular Identification of Four Uncommon Alpha Globin Variants in Thailand. Acta Haematologica, 2014, 131, 88-94.	1.4	14
78	An overview of current treatment strategies for Î²-thalassemia. Expert Opinion on Orphan Drugs, 2014, 2, 665-679.	0.8	8
79	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90.	1.4	8
80	Deferiprone for transfusional iron overload and its roles in developing countries. Expert Opinion on Orphan Drugs, 2014, 2, 189-200.	0.8	3
81	Variable Genotype-Phenotype Correlations in Patients With a Rare Nondeletional Î±-thalassemia; Hb Pak		

#	Article	IF	Citations
91	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfusion, 2013, 11, 108-22.	0.4	17
92	Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.. Blood, 2012, 120, 2126-2126.	1.4	2
93	Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA). Blood, 2012, 120, 3258-3258.	1.4	3
94	Twice Daily Dosing of Deferasirox Significantly Improves Clinical Efficacy in Transfusion Dependent Thalassemias Who Were Inadequate Responders to Standard Once Daily Dose. Blood, 2012, 120, 1026-1026.	1.4	0
95	Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology, 2011, 93, 319-328.	1.6	11
96	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
97	Continued Improvement and Normalization of Myocardial T2* In Patients with Î²-thalassemia Major Treated with Deferasirox (ExjadeÂ®) for up to 3 Years. Blood, 2010, 116, 4276-4276.	1.4	8
98	Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias. Blood, 2010, 116, 4272-4272.	1.4	1
99	Hb H disease: clinical course and disease modifiers. Hematology American Society of Hematology Education Program, 2009, 2009, 26-34.	2.5	140
100	Iron chelation therapy in the management of thalassemia: the Asian perspectives. International Journal of Hematology, 2009, 90, 435-445.	1.6	61
101	Clinical features and molecular analysis in Thai patients with HbH disease. Annals of Hematology, 2009, 88, 1185-1192.	1.8	91
102	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Î²-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062.	1.4	4
103	Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.. Blood, 2009, 114, 5111-5111.	1.4	1
104	Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with Î²-Thalassemia.. Blood, 2009, 114, 5106-5106.	1.4	1
105	Epigenetic Analysis of Beta-Globin Gene Cluster during Hematopoiesis.. Blood, 2008, 112, 1863-1863.	1.4	1
106	Two independent origins of Hb Dhonburi (Neapolis) [Î² 126 (H4) Valâ†'Gly]: An electrophoretically silent hemoglobin variant. Clinica Chimica Acta, 2007, 376, 179-183.	1.1	10
107	Osteopenia Is Commonly Present in Prepubertal Children with Severe Hb E/Î²thalassemia Despite Adequate Transfusion and Iron Chelation Therapy.. Blood, 2007, 110, 3830-3830.	1.4	3
108	Hb Woodville, a rare alpha-globin variant, caused by codon 6 mutation of the alpha1 gene. European Journal of Haematology, 2006, 76, 79-82.	2.2	1

#	Article	IF	Citations
109	Identification of a Novel IL7RA Mutation (444_450insA) Caused Marked Reduction in CD127 Expression from a Cohort Molecular Analysis of Severe Combined Immunodeficiency (Tâ^, B+, NK+ SCID) in Thailand.. Blood, 2006, 108, 1247-1247.	1.4	1
110	A Rare Association of Î±0-Thalassemia (â€“ â€“SEA) and an Initiation Codon Mutation (ATGâ†'A-G) of the Î±2 Gene Causes Hb H Disease in Thailand. Hemoglobin, 2005, 29, 235-240.	0.8	6
111	An Entirely Novel Form of Î± Thalassemia in Patients from the South Pacific Linked to Chromosome 16.. Blood, 2005, 106, 2688-2688.	1.4	4
112	Hematological parameters and red blood cell indices in healthy Thai children: a revision for 2005. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88 Suppl 8, S188-96.	0.1	1
113	Identification of Hb Q-India (îœ€64 Aspâ†'His) in Thailand. Hematology, 2004, 9, 151-155.	1.5	4
114	Acute haemolytic crisis in a Thai patient with homozygous haemoglobin Constant Spring (Hb CS/CS): a case report. Annals of Tropical Paediatrics, 2004, 24, 323-328.	1.0	11
115	Prevalence of HFE mutations among the Thai population and correlation with iron loading in haemoglobin E disorder*. European Journal of Haematology, 2004, 73, 43-49.	2.2	11
116	Co-inheritance of Hb Pak Num Po, a novel ?1 gene mutation, and ?0 thalassemia associated with transfusion-dependent Hb H disease. American Journal of Hematology, 2004, 75, 157-163.	4.1	28
117	Unusual phenotype of Hemoglobin EE with Hemoglobin H disease: a pitfall in clinical diagnosis and genetic counseling. Journal of Pediatrics, 2004, 144, 391-393.	1.8	6
118	Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with Î² thalassemia. Blood, 2004, 103, 3296-3299.	1.4	102
119	Dinucleotide deletion in -Î±3.7 allele causes a severe form of Î±+ thalassaemia. European Journal of Haematology, 2003, 71, 133-136.	2.2	8
120	De novo deletion within the telomeric region flanking the human Î± globin locus as a cause of Î± thalassaemia. British Journal of Haematology, 2003, 120, 867-875.	2.5	36
121	COMPOUND HETEROZYGOSITY FORÎ±⁰-THALASSEMIA (â^'â^'^{THAI}) AND Hb CONSTANT SPRING CAUSES SEVERE Hb H DISEASE. Hemoglobin, 2002, 26, 155-162.	0.8	17
122	Hb G-MAKASSAR [Î²6(A3)Gluâ†'Ala; CODON 6 (GAGâ†'GCG)]: MOLECULAR CHARACTERIZATION, CLINICAL, AND HEMATOLOGICAL EFFECTS. Hemoglobin, 2002, 26, 245-253.	0.8	20
123	Complex interactions of deltabeta hybrid haemoglobin (Hb Lepore-Hollandia) Hb E (beta26 GA) and alpha+ thalassaemia in a Thai family. European Journal of Haematology, 2002, 68, 107-111.	2.2	25
124	Baseline levels of plasma endothelin-1 (ET-1) and changes during transfusion in thalassemic patients. American Journal of Hematology, 2002, 70, 260-262.	4.1	10
125	Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of Î± thalassaemia (–MED /Î±TSaudi Î±). British Journal of Haematology, 2002, 117, 759-762.	2.5	38
126	Clinical phenotypes and molecular characterization of Hb H-PaksÃ© disease. Haematologica, 2002, 87, 117-25.	3.5	58

#	Article	IF	Citations
127	Allele related mutation specific-polymerase chain reaction for rapid diagnosis of Hb New York (beta) Tj ETQq1 1 0.784314 rgBT /Overl Chotmaihet Thangphaet, 2002, 85 Suppl 2, S558-63.	0.1	2
128	Bone mineral density in primarily preadolescent children with hemoglobin EÎ²â€thalassemia with different severities and transfusion requirements. Pediatric Blood and Cancer, 0, , .	1.5	0